Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 12/20 | 0.61 |
| ▸ | MMP2 | P08253 | 7/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.61 |
| ▸ | MMP1 | P03956 | 19/20 | 0.50 |
| ▸ | MMP3 | P08254 | 18/20 | 0.50 |
| ▸ | MMP7 | P09237 | 18/20 | 0.50 |
| ▸ | MMP13 | P45452 | 17/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656026 | 0.91 | MMP2 (0.52) | MMP9MMP2MMP12 | |
| SCHEMBL1655592 | 0.89 | ALDH1A1 (0.49) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL1656014 | 0.88 | MMP9 (0.61) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL1658459 | 0.87 | MMP9 (0.56) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL2922730 | 0.84 | MMP2 (0.45) | MMP9MMP2MMP12 | |
| SCHEMBL1655768 | 0.84 | MMP2 (0.66) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL1656257 | 0.83 | MMP9 (0.68) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL1656118 | 0.81 | MMP9 (0.72) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL2927547 | 0.81 | MMP9 (0.75) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL13201347 | 0.79 | MMP9 (0.61) | MMP9MMP2MMP12MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | claimed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | claimed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | claimed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | PNPO, NLRP3, CHRM3 | MMP9 1358/4885MMP2 2336/4885MMP12 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.